Facebook ends project to share data with healthcare orgs, hospitals

Facebook has been in the news lately, having to explain how millions of users' data have been misused. Now it has announced an end to plans to share user data with several major U.S. hospitals and organizations, including the American College of Cardiology.

“This work has not progressed past the planning phase, and we have not received, shared or analyzed anyone’s data,” Facebook said in a statement to CNBC.

Facebook planned to anonymize the information, so no individuals would be personally identified. The data were intended for use by medical researchers. But in light of the scandal surrounding political research organization Cambridge Analytica, Facebook has faced scrutiny over possible misuse of user data.

According to CNBC, Freddy Abnousi, MD, MBA, MSc, a cardiologist in Stanford, California, led the project out of Facebook’s experiment projects group. The goal was to use patient data along with social media information to improve patient care, focusing primarily on cardiovascular health.

The full story is available at the link below:

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.